nodes	percent_of_prediction	percent_of_DWPC	metapath
Diflunisal—osteoarthritis—Prednisone—systemic scleroderma	0.438	1	CpDpCtD
Diflunisal—UGT1A8—Mycophenolate mofetil—systemic scleroderma	0.314	0.702	CbGbCtD
Diflunisal—SLC22A6—Captopril—systemic scleroderma	0.0366	0.0818	CbGbCtD
Diflunisal—ALB—Captopril—systemic scleroderma	0.0312	0.0697	CbGbCtD
Diflunisal—ALB—Mycophenolate mofetil—systemic scleroderma	0.0246	0.0549	CbGbCtD
Diflunisal—ALB—Prednisone—systemic scleroderma	0.0196	0.0439	CbGbCtD
Diflunisal—SLC22A6—Methotrexate—systemic scleroderma	0.0116	0.0258	CbGbCtD
Diflunisal—ALB—Methotrexate—systemic scleroderma	0.00985	0.022	CbGbCtD
Diflunisal—PTGS2—skeletal joint—systemic scleroderma	0.00208	0.148	CbGeAlD
Diflunisal—UGT1A8—digestive system—systemic scleroderma	0.00158	0.112	CbGeAlD
Diflunisal—PTGS2—Fluocinonide—Mometasone—systemic scleroderma	0.00118	0.624	CbGdCrCtD
Diflunisal—TTR—connective tissue—systemic scleroderma	0.001	0.071	CbGeAlD
Diflunisal—PTGS1—artery—systemic scleroderma	0.000912	0.0646	CbGeAlD
Diflunisal—PTGS2—artery—systemic scleroderma	0.000872	0.0618	CbGeAlD
Diflunisal—PTGS1—endothelium—systemic scleroderma	0.000771	0.0546	CbGeAlD
Diflunisal—PTGS2—endothelium—systemic scleroderma	0.000737	0.0522	CbGeAlD
Diflunisal—TTR—digestive system—systemic scleroderma	0.000724	0.0513	CbGeAlD
Diflunisal—PTGS2—Fluticasone Propionate—Mometasone—systemic scleroderma	0.000711	0.376	CbGdCrCtD
Diflunisal—PTGS1—blood vessel—systemic scleroderma	0.000711	0.0504	CbGeAlD
Diflunisal—PTGS2—blood vessel—systemic scleroderma	0.000679	0.0481	CbGeAlD
Diflunisal—TTR—lung—systemic scleroderma	0.000604	0.0428	CbGeAlD
Diflunisal—PTGS1—connective tissue—systemic scleroderma	0.000364	0.0258	CbGeAlD
Diflunisal—PTGS2—connective tissue—systemic scleroderma	0.000348	0.0247	CbGeAlD
Diflunisal—PTGS1—smooth muscle tissue—systemic scleroderma	0.000333	0.0236	CbGeAlD
Diflunisal—PTGS1—skin of body—systemic scleroderma	0.000329	0.0233	CbGeAlD
Diflunisal—PTGS2—smooth muscle tissue—systemic scleroderma	0.000319	0.0226	CbGeAlD
Diflunisal—PTGS2—skin of body—systemic scleroderma	0.000315	0.0223	CbGeAlD
Diflunisal—PTGS1—digestive system—systemic scleroderma	0.000263	0.0186	CbGeAlD
Diflunisal—PTGS2—digestive system—systemic scleroderma	0.000252	0.0178	CbGeAlD
Diflunisal—PTGS1—tendon—systemic scleroderma	0.00025	0.0177	CbGeAlD
Diflunisal—PTGS2—tendon—systemic scleroderma	0.000239	0.017	CbGeAlD
Diflunisal—PTGS1—lung—systemic scleroderma	0.00022	0.0156	CbGeAlD
Diflunisal—PTGS2—lung—systemic scleroderma	0.00021	0.0149	CbGeAlD
Diflunisal—Gastrointestinal haemorrhage—Prednisone—systemic scleroderma	0.000204	0.00209	CcSEcCtD
Diflunisal—Constipation—Captopril—systemic scleroderma	0.000204	0.00208	CcSEcCtD
Diflunisal—Flatulence—Lisinopril—systemic scleroderma	0.000204	0.00208	CcSEcCtD
Diflunisal—Thrombocytopenia—Azathioprine—systemic scleroderma	0.000204	0.00208	CcSEcCtD
Diflunisal—Tension—Lisinopril—systemic scleroderma	0.000203	0.00208	CcSEcCtD
Diflunisal—Palpitations—Mycophenolic acid—systemic scleroderma	0.000203	0.00208	CcSEcCtD
Diflunisal—Loss of consciousness—Mycophenolic acid—systemic scleroderma	0.000202	0.00206	CcSEcCtD
Diflunisal—Nervousness—Lisinopril—systemic scleroderma	0.000201	0.00205	CcSEcCtD
Diflunisal—Visual impairment—Mycophenolate mofetil—systemic scleroderma	0.000201	0.00205	CcSEcCtD
Diflunisal—Vomiting—Pentoxifylline—systemic scleroderma	0.0002	0.00205	CcSEcCtD
Diflunisal—Muscle spasms—Lisinopril—systemic scleroderma	0.000199	0.00203	CcSEcCtD
Diflunisal—Rash—Pentoxifylline—systemic scleroderma	0.000199	0.00203	CcSEcCtD
Diflunisal—Dermatitis—Pentoxifylline—systemic scleroderma	0.000198	0.00203	CcSEcCtD
Diflunisal—Headache—Pentoxifylline—systemic scleroderma	0.000197	0.00202	CcSEcCtD
Diflunisal—Anaphylactic shock—Leflunomide—systemic scleroderma	0.000197	0.00201	CcSEcCtD
Diflunisal—Feeling abnormal—Captopril—systemic scleroderma	0.000197	0.00201	CcSEcCtD
Diflunisal—Chest pain—Mycophenolic acid—systemic scleroderma	0.000196	0.002	CcSEcCtD
Diflunisal—Vision blurred—Lisinopril—systemic scleroderma	0.000195	0.00199	CcSEcCtD
Diflunisal—Gastrointestinal pain—Captopril—systemic scleroderma	0.000195	0.00199	CcSEcCtD
Diflunisal—Asthenia—Mometasone—systemic scleroderma	0.000195	0.00199	CcSEcCtD
Diflunisal—Photosensitivity—Methotrexate—systemic scleroderma	0.000194	0.00199	CcSEcCtD
Diflunisal—Tinnitus—Mycophenolate mofetil—systemic scleroderma	0.000194	0.00198	CcSEcCtD
Diflunisal—Thrombocytopenia—Leflunomide—systemic scleroderma	0.000193	0.00197	CcSEcCtD
Diflunisal—Pruritus—Mometasone—systemic scleroderma	0.000192	0.00196	CcSEcCtD
Diflunisal—Hyperhidrosis—Leflunomide—systemic scleroderma	0.00019	0.00194	CcSEcCtD
Diflunisal—Angioedema—Lisinopril—systemic scleroderma	0.000189	0.00193	CcSEcCtD
Diflunisal—Confusional state—Mycophenolic acid—systemic scleroderma	0.000189	0.00193	CcSEcCtD
Diflunisal—Body temperature increased—Captopril—systemic scleroderma	0.000189	0.00193	CcSEcCtD
Diflunisal—Oedema—Mycophenolic acid—systemic scleroderma	0.000188	0.00192	CcSEcCtD
Diflunisal—Anorexia—Leflunomide—systemic scleroderma	0.000188	0.00192	CcSEcCtD
Diflunisal—Nausea—Pentoxifylline—systemic scleroderma	0.000187	0.00191	CcSEcCtD
Diflunisal—Vertigo—Lisinopril—systemic scleroderma	0.000186	0.0019	CcSEcCtD
Diflunisal—Diarrhoea—Mometasone—systemic scleroderma	0.000186	0.0019	CcSEcCtD
Diflunisal—Syncope—Lisinopril—systemic scleroderma	0.000186	0.0019	CcSEcCtD
Diflunisal—Shock—Mycophenolic acid—systemic scleroderma	0.000185	0.00189	CcSEcCtD
Diflunisal—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000184	0.00188	CcSEcCtD
Diflunisal—Palpitations—Lisinopril—systemic scleroderma	0.000183	0.00187	CcSEcCtD
Diflunisal—Loss of consciousness—Lisinopril—systemic scleroderma	0.000182	0.00186	CcSEcCtD
Diflunisal—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.000181	0.00185	CcSEcCtD
Diflunisal—Dermatitis exfoliative—Methotrexate—systemic scleroderma	0.000181	0.00185	CcSEcCtD
Diflunisal—Visual disturbance—Methotrexate—systemic scleroderma	0.00018	0.00184	CcSEcCtD
Diflunisal—Anorexia—Mycophenolic acid—systemic scleroderma	0.000179	0.00183	CcSEcCtD
Diflunisal—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.000179	0.00183	CcSEcCtD
Diflunisal—Tension—Mycophenolate mofetil—systemic scleroderma	0.000178	0.00182	CcSEcCtD
Diflunisal—Insomnia—Leflunomide—systemic scleroderma	0.000178	0.00182	CcSEcCtD
Diflunisal—Paraesthesia—Leflunomide—systemic scleroderma	0.000177	0.0018	CcSEcCtD
Diflunisal—Chest pain—Lisinopril—systemic scleroderma	0.000176	0.0018	CcSEcCtD
Diflunisal—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.000176	0.0018	CcSEcCtD
Diflunisal—Dyspnoea—Leflunomide—systemic scleroderma	0.000175	0.00179	CcSEcCtD
Diflunisal—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000174	0.00178	CcSEcCtD
Diflunisal—Dyspepsia—Leflunomide—systemic scleroderma	0.000173	0.00177	CcSEcCtD
Diflunisal—Vomiting—Mometasone—systemic scleroderma	0.000173	0.00176	CcSEcCtD
Diflunisal—Feeling abnormal—Azathioprine—systemic scleroderma	0.000172	0.00175	CcSEcCtD
Diflunisal—Rash—Mometasone—systemic scleroderma	0.000171	0.00175	CcSEcCtD
Diflunisal—Asthenia—Captopril—systemic scleroderma	0.000171	0.00175	CcSEcCtD
Diflunisal—Dermatitis—Mometasone—systemic scleroderma	0.000171	0.00175	CcSEcCtD
Diflunisal—Decreased appetite—Leflunomide—systemic scleroderma	0.000171	0.00175	CcSEcCtD
Diflunisal—Confusional state—Lisinopril—systemic scleroderma	0.00017	0.00174	CcSEcCtD
Diflunisal—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00017	0.00174	CcSEcCtD
Diflunisal—Headache—Mometasone—systemic scleroderma	0.00017	0.00174	CcSEcCtD
Diflunisal—Insomnia—Mycophenolic acid—systemic scleroderma	0.00017	0.00173	CcSEcCtD
Diflunisal—Fatigue—Leflunomide—systemic scleroderma	0.00017	0.00173	CcSEcCtD
Diflunisal—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000169	0.00173	CcSEcCtD
Diflunisal—Oedema—Lisinopril—systemic scleroderma	0.000169	0.00173	CcSEcCtD
Diflunisal—Pruritus—Captopril—systemic scleroderma	0.000169	0.00172	CcSEcCtD
Diflunisal—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000169	0.00172	CcSEcCtD
Diflunisal—Constipation—Leflunomide—systemic scleroderma	0.000168	0.00172	CcSEcCtD
Diflunisal—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000167	0.00171	CcSEcCtD
Diflunisal—Somnolence—Mycophenolic acid—systemic scleroderma	0.000167	0.0017	CcSEcCtD
Diflunisal—Shock—Lisinopril—systemic scleroderma	0.000166	0.0017	CcSEcCtD
Diflunisal—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000166	0.00169	CcSEcCtD
Diflunisal—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000166	0.00169	CcSEcCtD
Diflunisal—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000165	0.00169	CcSEcCtD
Diflunisal—Body temperature increased—Azathioprine—systemic scleroderma	0.000165	0.00168	CcSEcCtD
Diflunisal—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000163	0.00167	CcSEcCtD
Diflunisal—Diarrhoea—Captopril—systemic scleroderma	0.000163	0.00167	CcSEcCtD
Diflunisal—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000163	0.00167	CcSEcCtD
Diflunisal—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000163	0.00167	CcSEcCtD
Diflunisal—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000163	0.00166	CcSEcCtD
Diflunisal—Feeling abnormal—Leflunomide—systemic scleroderma	0.000162	0.00166	CcSEcCtD
Diflunisal—Fatigue—Mycophenolic acid—systemic scleroderma	0.000162	0.00165	CcSEcCtD
Diflunisal—Nausea—Mometasone—systemic scleroderma	0.000161	0.00165	CcSEcCtD
Diflunisal—Anorexia—Lisinopril—systemic scleroderma	0.000161	0.00165	CcSEcCtD
Diflunisal—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000161	0.00164	CcSEcCtD
Diflunisal—Constipation—Mycophenolic acid—systemic scleroderma	0.00016	0.00164	CcSEcCtD
Diflunisal—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.00016	0.00164	CcSEcCtD
Diflunisal—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000159	0.00163	CcSEcCtD
Diflunisal—Dizziness—Captopril—systemic scleroderma	0.000158	0.00161	CcSEcCtD
Diflunisal—Urticaria—Leflunomide—systemic scleroderma	0.000156	0.0016	CcSEcCtD
Diflunisal—Body temperature increased—Leflunomide—systemic scleroderma	0.000156	0.00159	CcSEcCtD
Diflunisal—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000155	0.00158	CcSEcCtD
Diflunisal—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000154	0.00158	CcSEcCtD
Diflunisal—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000154	0.00157	CcSEcCtD
Diflunisal—Hypersensitivity—Azathioprine—systemic scleroderma	0.000153	0.00157	CcSEcCtD
Diflunisal—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000153	0.00157	CcSEcCtD
Diflunisal—Insomnia—Lisinopril—systemic scleroderma	0.000153	0.00156	CcSEcCtD
Diflunisal—Paraesthesia—Lisinopril—systemic scleroderma	0.000152	0.00155	CcSEcCtD
Diflunisal—Vomiting—Captopril—systemic scleroderma	0.000152	0.00155	CcSEcCtD
Diflunisal—Dyspnoea—Lisinopril—systemic scleroderma	0.000151	0.00154	CcSEcCtD
Diflunisal—Rash—Captopril—systemic scleroderma	0.00015	0.00154	CcSEcCtD
Diflunisal—Dermatitis—Captopril—systemic scleroderma	0.00015	0.00154	CcSEcCtD
Diflunisal—Somnolence—Lisinopril—systemic scleroderma	0.00015	0.00153	CcSEcCtD
Diflunisal—Headache—Captopril—systemic scleroderma	0.00015	0.00153	CcSEcCtD
Diflunisal—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000149	0.00153	CcSEcCtD
Diflunisal—Dyspepsia—Lisinopril—systemic scleroderma	0.000149	0.00152	CcSEcCtD
Diflunisal—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000148	0.00152	CcSEcCtD
Diflunisal—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000148	0.00151	CcSEcCtD
Diflunisal—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000148	0.00151	CcSEcCtD
Diflunisal—Decreased appetite—Lisinopril—systemic scleroderma	0.000147	0.0015	CcSEcCtD
Diflunisal—Fatigue—Lisinopril—systemic scleroderma	0.000146	0.00149	CcSEcCtD
Diflunisal—Shock—Mycophenolate mofetil—systemic scleroderma	0.000146	0.00149	CcSEcCtD
Diflunisal—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000145	0.00148	CcSEcCtD
Diflunisal—Hypersensitivity—Leflunomide—systemic scleroderma	0.000145	0.00148	CcSEcCtD
Diflunisal—Constipation—Lisinopril—systemic scleroderma	0.000145	0.00148	CcSEcCtD
Diflunisal—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000143	0.00146	CcSEcCtD
Diflunisal—Diarrhoea—Azathioprine—systemic scleroderma	0.000143	0.00146	CcSEcCtD
Diflunisal—Nausea—Captopril—systemic scleroderma	0.000142	0.00145	CcSEcCtD
Diflunisal—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000141	0.00144	CcSEcCtD
Diflunisal—Asthenia—Leflunomide—systemic scleroderma	0.000141	0.00144	CcSEcCtD
Diflunisal—Hallucination—Prednisone—systemic scleroderma	0.000141	0.00144	CcSEcCtD
Diflunisal—Feeling abnormal—Lisinopril—systemic scleroderma	0.000139	0.00142	CcSEcCtD
Diflunisal—Pruritus—Leflunomide—systemic scleroderma	0.000139	0.00142	CcSEcCtD
Diflunisal—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000138	0.00141	CcSEcCtD
Diflunisal—Dysuria—Methotrexate—systemic scleroderma	0.000138	0.00141	CcSEcCtD
Diflunisal—Dizziness—Azathioprine—systemic scleroderma	0.000138	0.00141	CcSEcCtD
Diflunisal—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000135	0.00138	CcSEcCtD
Diflunisal—Asthenia—Mycophenolic acid—systemic scleroderma	0.000135	0.00138	CcSEcCtD
Diflunisal—Diarrhoea—Leflunomide—systemic scleroderma	0.000135	0.00137	CcSEcCtD
Diflunisal—Urticaria—Lisinopril—systemic scleroderma	0.000134	0.00137	CcSEcCtD
Diflunisal—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000134	0.00137	CcSEcCtD
Diflunisal—Body temperature increased—Lisinopril—systemic scleroderma	0.000134	0.00136	CcSEcCtD
Diflunisal—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000133	0.00136	CcSEcCtD
Diflunisal—Pruritus—Mycophenolic acid—systemic scleroderma	0.000133	0.00136	CcSEcCtD
Diflunisal—Vomiting—Azathioprine—systemic scleroderma	0.000132	0.00135	CcSEcCtD
Diflunisal—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000132	0.00135	CcSEcCtD
Diflunisal—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000132	0.00134	CcSEcCtD
Diflunisal—Rash—Azathioprine—systemic scleroderma	0.000131	0.00134	CcSEcCtD
Diflunisal—Dermatitis—Azathioprine—systemic scleroderma	0.000131	0.00134	CcSEcCtD
Diflunisal—Flushing—Prednisone—systemic scleroderma	0.000131	0.00134	CcSEcCtD
Diflunisal—Headache—Azathioprine—systemic scleroderma	0.00013	0.00133	CcSEcCtD
Diflunisal—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.00013	0.00133	CcSEcCtD
Diflunisal—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.00013	0.00133	CcSEcCtD
Diflunisal—Dizziness—Leflunomide—systemic scleroderma	0.00013	0.00133	CcSEcCtD
Diflunisal—Renal failure—Methotrexate—systemic scleroderma	0.000129	0.00132	CcSEcCtD
Diflunisal—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000129	0.00131	CcSEcCtD
Diflunisal—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000128	0.00131	CcSEcCtD
Diflunisal—Stomatitis—Methotrexate—systemic scleroderma	0.000128	0.00131	CcSEcCtD
Diflunisal—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000127	0.00129	CcSEcCtD
Diflunisal—Sweating—Methotrexate—systemic scleroderma	0.000126	0.00129	CcSEcCtD
Diflunisal—Haematuria—Methotrexate—systemic scleroderma	0.000125	0.00128	CcSEcCtD
Diflunisal—Vomiting—Leflunomide—systemic scleroderma	0.000125	0.00128	CcSEcCtD
Diflunisal—Hypersensitivity—Lisinopril—systemic scleroderma	0.000125	0.00127	CcSEcCtD
Diflunisal—Dizziness—Mycophenolic acid—systemic scleroderma	0.000124	0.00127	CcSEcCtD
Diflunisal—Rash—Leflunomide—systemic scleroderma	0.000124	0.00127	CcSEcCtD
Diflunisal—Dermatitis—Leflunomide—systemic scleroderma	0.000124	0.00127	CcSEcCtD
Diflunisal—Nausea—Azathioprine—systemic scleroderma	0.000124	0.00126	CcSEcCtD
Diflunisal—Headache—Leflunomide—systemic scleroderma	0.000123	0.00126	CcSEcCtD
Diflunisal—Agranulocytosis—Methotrexate—systemic scleroderma	0.000123	0.00125	CcSEcCtD
Diflunisal—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000122	0.00125	CcSEcCtD
Diflunisal—Asthenia—Lisinopril—systemic scleroderma	0.000121	0.00124	CcSEcCtD
Diflunisal—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000121	0.00124	CcSEcCtD
Diflunisal—Pruritus—Lisinopril—systemic scleroderma	0.00012	0.00122	CcSEcCtD
Diflunisal—Vomiting—Mycophenolic acid—systemic scleroderma	0.000119	0.00122	CcSEcCtD
Diflunisal—Rash—Mycophenolic acid—systemic scleroderma	0.000118	0.00121	CcSEcCtD
Diflunisal—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000118	0.00121	CcSEcCtD
Diflunisal—Hepatitis—Methotrexate—systemic scleroderma	0.000118	0.00121	CcSEcCtD
Diflunisal—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000118	0.0012	CcSEcCtD
Diflunisal—Headache—Mycophenolic acid—systemic scleroderma	0.000118	0.0012	CcSEcCtD
Diflunisal—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000117	0.0012	CcSEcCtD
Diflunisal—Nausea—Leflunomide—systemic scleroderma	0.000117	0.00119	CcSEcCtD
Diflunisal—Vision blurred—Prednisone—systemic scleroderma	0.000116	0.00118	CcSEcCtD
Diflunisal—Diarrhoea—Lisinopril—systemic scleroderma	0.000116	0.00118	CcSEcCtD
Diflunisal—Visual impairment—Methotrexate—systemic scleroderma	0.000114	0.00116	CcSEcCtD
Diflunisal—Angioedema—Prednisone—systemic scleroderma	0.000112	0.00115	CcSEcCtD
Diflunisal—Dizziness—Lisinopril—systemic scleroderma	0.000112	0.00114	CcSEcCtD
Diflunisal—Erythema multiforme—Methotrexate—systemic scleroderma	0.000112	0.00114	CcSEcCtD
Diflunisal—Nausea—Mycophenolic acid—systemic scleroderma	0.000111	0.00114	CcSEcCtD
Diflunisal—Vertigo—Prednisone—systemic scleroderma	0.000111	0.00113	CcSEcCtD
Diflunisal—Syncope—Prednisone—systemic scleroderma	0.00011	0.00113	CcSEcCtD
Diflunisal—Tinnitus—Methotrexate—systemic scleroderma	0.00011	0.00112	CcSEcCtD
Diflunisal—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000109	0.00111	CcSEcCtD
Diflunisal—Loss of consciousness—Prednisone—systemic scleroderma	0.000108	0.0011	CcSEcCtD
Diflunisal—Vomiting—Lisinopril—systemic scleroderma	0.000107	0.0011	CcSEcCtD
Diflunisal—Rash—Lisinopril—systemic scleroderma	0.000107	0.00109	CcSEcCtD
Diflunisal—Dermatitis—Lisinopril—systemic scleroderma	0.000106	0.00109	CcSEcCtD
Diflunisal—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000106	0.00109	CcSEcCtD
Diflunisal—Headache—Lisinopril—systemic scleroderma	0.000106	0.00108	CcSEcCtD
Diflunisal—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000105	0.00107	CcSEcCtD
Diflunisal—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000101	0.00103	CcSEcCtD
Diflunisal—Nausea—Lisinopril—systemic scleroderma	0.0001	0.00103	CcSEcCtD
Diflunisal—Oedema—Prednisone—systemic scleroderma	0.0001	0.00103	CcSEcCtD
Diflunisal—Anaphylactic shock—Prednisone—systemic scleroderma	0.0001	0.00103	CcSEcCtD
Diflunisal—Shock—Prednisone—systemic scleroderma	9.88e-05	0.00101	CcSEcCtD
Diflunisal—Dizziness—Mycophenolate mofetil—systemic scleroderma	9.79e-05	0.001	CcSEcCtD
Diflunisal—Hyperhidrosis—Prednisone—systemic scleroderma	9.71e-05	0.000991	CcSEcCtD
Diflunisal—Vision blurred—Methotrexate—systemic scleroderma	9.69e-05	0.000989	CcSEcCtD
Diflunisal—Anorexia—Prednisone—systemic scleroderma	9.57e-05	0.000977	CcSEcCtD
Diflunisal—Vomiting—Mycophenolate mofetil—systemic scleroderma	9.42e-05	0.000962	CcSEcCtD
Diflunisal—Rash—Mycophenolate mofetil—systemic scleroderma	9.34e-05	0.000954	CcSEcCtD
Diflunisal—Dermatitis—Mycophenolate mofetil—systemic scleroderma	9.33e-05	0.000953	CcSEcCtD
Diflunisal—Headache—Mycophenolate mofetil—systemic scleroderma	9.28e-05	0.000948	CcSEcCtD
Diflunisal—Vertigo—Methotrexate—systemic scleroderma	9.24e-05	0.000943	CcSEcCtD
Diflunisal—Insomnia—Prednisone—systemic scleroderma	9.08e-05	0.000927	CcSEcCtD
Diflunisal—Paraesthesia—Prednisone—systemic scleroderma	9.01e-05	0.000921	CcSEcCtD
Diflunisal—Dyspepsia—Prednisone—systemic scleroderma	8.84e-05	0.000903	CcSEcCtD
Diflunisal—Nausea—Mycophenolate mofetil—systemic scleroderma	8.8e-05	0.000898	CcSEcCtD
Diflunisal—Chest pain—Methotrexate—systemic scleroderma	8.75e-05	0.000894	CcSEcCtD
Diflunisal—Decreased appetite—Prednisone—systemic scleroderma	8.73e-05	0.000891	CcSEcCtD
Diflunisal—Fatigue—Prednisone—systemic scleroderma	8.66e-05	0.000884	CcSEcCtD
Diflunisal—Constipation—Prednisone—systemic scleroderma	8.58e-05	0.000877	CcSEcCtD
Diflunisal—Confusional state—Methotrexate—systemic scleroderma	8.46e-05	0.000864	CcSEcCtD
Diflunisal—Anaphylactic shock—Methotrexate—systemic scleroderma	8.39e-05	0.000857	CcSEcCtD
Diflunisal—Feeling abnormal—Prednisone—systemic scleroderma	8.27e-05	0.000845	CcSEcCtD
Diflunisal—Thrombocytopenia—Methotrexate—systemic scleroderma	8.21e-05	0.000839	CcSEcCtD
Diflunisal—Gastrointestinal pain—Prednisone—systemic scleroderma	8.21e-05	0.000838	CcSEcCtD
Diflunisal—Hyperhidrosis—Methotrexate—systemic scleroderma	8.11e-05	0.000828	CcSEcCtD
Diflunisal—Anorexia—Methotrexate—systemic scleroderma	8e-05	0.000817	CcSEcCtD
Diflunisal—Urticaria—Prednisone—systemic scleroderma	7.98e-05	0.000815	CcSEcCtD
Diflunisal—Body temperature increased—Prednisone—systemic scleroderma	7.94e-05	0.000811	CcSEcCtD
Diflunisal—Insomnia—Methotrexate—systemic scleroderma	7.59e-05	0.000775	CcSEcCtD
Diflunisal—Paraesthesia—Methotrexate—systemic scleroderma	7.53e-05	0.000769	CcSEcCtD
Diflunisal—Dyspnoea—Methotrexate—systemic scleroderma	7.48e-05	0.000764	CcSEcCtD
Diflunisal—Somnolence—Methotrexate—systemic scleroderma	7.46e-05	0.000762	CcSEcCtD
Diflunisal—Hypersensitivity—Prednisone—systemic scleroderma	7.4e-05	0.000755	CcSEcCtD
Diflunisal—Dyspepsia—Methotrexate—systemic scleroderma	7.39e-05	0.000754	CcSEcCtD
Diflunisal—Decreased appetite—Methotrexate—systemic scleroderma	7.29e-05	0.000745	CcSEcCtD
Diflunisal—Fatigue—Methotrexate—systemic scleroderma	7.23e-05	0.000739	CcSEcCtD
Diflunisal—Asthenia—Prednisone—systemic scleroderma	7.2e-05	0.000736	CcSEcCtD
Diflunisal—Pruritus—Prednisone—systemic scleroderma	7.1e-05	0.000725	CcSEcCtD
Diflunisal—Feeling abnormal—Methotrexate—systemic scleroderma	6.91e-05	0.000706	CcSEcCtD
Diflunisal—Diarrhoea—Prednisone—systemic scleroderma	6.87e-05	0.000702	CcSEcCtD
Diflunisal—Gastrointestinal pain—Methotrexate—systemic scleroderma	6.86e-05	0.000701	CcSEcCtD
Diflunisal—Urticaria—Methotrexate—systemic scleroderma	6.67e-05	0.000681	CcSEcCtD
Diflunisal—Dizziness—Prednisone—systemic scleroderma	6.64e-05	0.000678	CcSEcCtD
Diflunisal—Body temperature increased—Methotrexate—systemic scleroderma	6.63e-05	0.000677	CcSEcCtD
Diflunisal—Vomiting—Prednisone—systemic scleroderma	6.38e-05	0.000652	CcSEcCtD
Diflunisal—TTR—Retinoid metabolism and transport—HSPG2—systemic scleroderma	6.34e-05	0.0885	CbGpPWpGaD
Diflunisal—Rash—Prednisone—systemic scleroderma	6.33e-05	0.000646	CcSEcCtD
Diflunisal—Dermatitis—Prednisone—systemic scleroderma	6.32e-05	0.000646	CcSEcCtD
Diflunisal—Headache—Prednisone—systemic scleroderma	6.29e-05	0.000642	CcSEcCtD
Diflunisal—TTR—Non-integrin membrane-ECM interactions—HSPG2—systemic scleroderma	6.22e-05	0.0868	CbGpPWpGaD
Diflunisal—Hypersensitivity—Methotrexate—systemic scleroderma	6.18e-05	0.000631	CcSEcCtD
Diflunisal—Asthenia—Methotrexate—systemic scleroderma	6.02e-05	0.000615	CcSEcCtD
Diflunisal—Nausea—Prednisone—systemic scleroderma	5.96e-05	0.000609	CcSEcCtD
Diflunisal—Pruritus—Methotrexate—systemic scleroderma	5.94e-05	0.000606	CcSEcCtD
Diflunisal—Diarrhoea—Methotrexate—systemic scleroderma	5.74e-05	0.000586	CcSEcCtD
Diflunisal—Dizziness—Methotrexate—systemic scleroderma	5.55e-05	0.000567	CcSEcCtD
Diflunisal—Vomiting—Methotrexate—systemic scleroderma	5.33e-05	0.000545	CcSEcCtD
Diflunisal—Rash—Methotrexate—systemic scleroderma	5.29e-05	0.00054	CcSEcCtD
Diflunisal—Dermatitis—Methotrexate—systemic scleroderma	5.29e-05	0.00054	CcSEcCtD
Diflunisal—Headache—Methotrexate—systemic scleroderma	5.26e-05	0.000537	CcSEcCtD
Diflunisal—Nausea—Methotrexate—systemic scleroderma	4.98e-05	0.000509	CcSEcCtD
Diflunisal—TTR—Amyloids—TGFBI—systemic scleroderma	4.66e-05	0.065	CbGpPWpGaD
Diflunisal—TTR—Amyloids—HSPG2—systemic scleroderma	3.71e-05	0.0518	CbGpPWpGaD
Diflunisal—TTR—Diseases associated with visual transduction—HSPG2—systemic scleroderma	3.24e-05	0.0452	CbGpPWpGaD
Diflunisal—PTGS2—Spinal Cord Injury—AIF1—systemic scleroderma	2.09e-05	0.0291	CbGpPWpGaD
Diflunisal—TTR—Extracellular matrix organization—FBN1—systemic scleroderma	2.04e-05	0.0285	CbGpPWpGaD
Diflunisal—ALB—Lipoprotein metabolism—HSPG2—systemic scleroderma	1.93e-05	0.027	CbGpPWpGaD
Diflunisal—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—systemic scleroderma	1.8e-05	0.0251	CbGpPWpGaD
Diflunisal—PTGS1—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	1.63e-05	0.0228	CbGpPWpGaD
Diflunisal—ALB—Binding and Uptake of Ligands by Scavenger Receptors—COL1A2—systemic scleroderma	1.51e-05	0.021	CbGpPWpGaD
Diflunisal—TTR—Extracellular matrix organization—COL1A2—systemic scleroderma	1.43e-05	0.0199	CbGpPWpGaD
Diflunisal—TTR—Extracellular matrix organization—HSPG2—systemic scleroderma	1.43e-05	0.0199	CbGpPWpGaD
Diflunisal—TTR—Non-integrin membrane-ECM interactions—TGFB1—systemic scleroderma	1.36e-05	0.0189	CbGpPWpGaD
Diflunisal—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—systemic scleroderma	1.32e-05	0.0183	CbGpPWpGaD
Diflunisal—TTR—Extracellular matrix organization—ITGAM—systemic scleroderma	1.3e-05	0.0181	CbGpPWpGaD
Diflunisal—PTGS2—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	1.29e-05	0.0181	CbGpPWpGaD
Diflunisal—ALB—Lipid and lipoprotein metabolism—HSPG2—systemic scleroderma	1.29e-05	0.0179	CbGpPWpGaD
Diflunisal—ALB—Folate Metabolism—CSF1—systemic scleroderma	1.13e-05	0.0157	CbGpPWpGaD
Diflunisal—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—systemic scleroderma	1.09e-05	0.0153	CbGpPWpGaD
Diflunisal—PTGS2—C-MYB transcription factor network—COL1A2—systemic scleroderma	1.05e-05	0.0146	CbGpPWpGaD
Diflunisal—PTGS2—Spinal Cord Injury—TNFSF13—systemic scleroderma	1.02e-05	0.0142	CbGpPWpGaD
Diflunisal—ALB—Platelet degranulation—SELP—systemic scleroderma	1e-05	0.014	CbGpPWpGaD
Diflunisal—ALB—Response to elevated platelet cytosolic Ca2+—SELP—systemic scleroderma	9.55e-06	0.0133	CbGpPWpGaD
Diflunisal—PTGS2—Spinal Cord Injury—SELP—systemic scleroderma	9.08e-06	0.0127	CbGpPWpGaD
Diflunisal—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—systemic scleroderma	8.51e-06	0.0119	CbGpPWpGaD
Diflunisal—PTGS2—Spinal Cord Injury—RHOB—systemic scleroderma	8.48e-06	0.0118	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	8.37e-06	0.0117	CbGpPWpGaD
Diflunisal—TTR—Extracellular matrix organization—MMP1—systemic scleroderma	6.5e-06	0.00907	CbGpPWpGaD
Diflunisal—TTR—Disease—SMAD7—systemic scleroderma	5.64e-06	0.00786	CbGpPWpGaD
Diflunisal—TTR—Disease—TGFBI—systemic scleroderma	5.15e-06	0.00719	CbGpPWpGaD
Diflunisal—TTR—Extracellular matrix organization—MMP2—systemic scleroderma	5.03e-06	0.00702	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—HSPG2—systemic scleroderma	4.83e-06	0.00674	CbGpPWpGaD
Diflunisal—PTGS1—Selenium Micronutrient Network—CCL2—systemic scleroderma	4.71e-06	0.00658	CbGpPWpGaD
Diflunisal—ALB—Vitamin B12 Metabolism—CCL2—systemic scleroderma	4.68e-06	0.00654	CbGpPWpGaD
Diflunisal—ALB—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	4.45e-06	0.00621	CbGpPWpGaD
Diflunisal—PTGS2—Spinal Cord Injury—IL1A—systemic scleroderma	4.3e-06	0.00601	CbGpPWpGaD
Diflunisal—ALB—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	4.15e-06	0.00579	CbGpPWpGaD
Diflunisal—TTR—Disease—HSPG2—systemic scleroderma	4.11e-06	0.00574	CbGpPWpGaD
Diflunisal—TTR—Disease—CSK—systemic scleroderma	3.97e-06	0.00554	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—SMAD7—systemic scleroderma	3.95e-06	0.00551	CbGpPWpGaD
Diflunisal—ALB—Folate Metabolism—CCL2—systemic scleroderma	3.81e-06	0.00532	CbGpPWpGaD
Diflunisal—TTR—Extracellular matrix organization—MMP9—systemic scleroderma	3.78e-06	0.00528	CbGpPWpGaD
Diflunisal—ALB—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	3.78e-06	0.00528	CbGpPWpGaD
Diflunisal—PTGS2—Selenium Micronutrient Network—CCL2—systemic scleroderma	3.74e-06	0.00522	CbGpPWpGaD
Diflunisal—TTR—Disease—CD247—systemic scleroderma	3.73e-06	0.00521	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—CTGF—systemic scleroderma	3.66e-06	0.00511	CbGpPWpGaD
Diflunisal—PTGS1—Selenium Micronutrient Network—IL1B—systemic scleroderma	3.58e-06	0.00499	CbGpPWpGaD
Diflunisal—ALB—Vitamin B12 Metabolism—IL1B—systemic scleroderma	3.55e-06	0.00496	CbGpPWpGaD
Diflunisal—TTR—Extracellular matrix organization—TGFB1—systemic scleroderma	3.12e-06	0.00435	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—RHOB—systemic scleroderma	3.05e-06	0.00426	CbGpPWpGaD
Diflunisal—ALB—Selenium Micronutrient Network—CCL2—systemic scleroderma	3.03e-06	0.00422	CbGpPWpGaD
Diflunisal—PTGS2—Spinal Cord Injury—CCL2—systemic scleroderma	2.96e-06	0.00413	CbGpPWpGaD
Diflunisal—ALB—Folate Metabolism—IL1B—systemic scleroderma	2.89e-06	0.00403	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—HSPG2—systemic scleroderma	2.88e-06	0.00402	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.86e-06	0.00399	CbGpPWpGaD
Diflunisal—PTGS2—Selenium Micronutrient Network—IL1B—systemic scleroderma	2.84e-06	0.00396	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—CSK—systemic scleroderma	2.78e-06	0.00388	CbGpPWpGaD
Diflunisal—ALB—Selenium Micronutrient Network—IL1B—systemic scleroderma	2.3e-06	0.0032	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—SELP—systemic scleroderma	2.29e-06	0.0032	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.27e-06	0.00317	CbGpPWpGaD
Diflunisal—PTGS2—Spinal Cord Injury—IL1B—systemic scleroderma	2.24e-06	0.00313	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.17e-06	0.00303	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—RHOB—systemic scleroderma	2.14e-06	0.00299	CbGpPWpGaD
Diflunisal—PTGS2—Spinal Cord Injury—MMP9—systemic scleroderma	2.12e-06	0.00295	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—CSK—systemic scleroderma	1.95e-06	0.00272	CbGpPWpGaD
Diflunisal—ALB—Platelet degranulation—TGFB1—systemic scleroderma	1.93e-06	0.00269	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.84e-06	0.00256	CbGpPWpGaD
Diflunisal—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	1.83e-06	0.00256	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—ITGAM—systemic scleroderma	1.83e-06	0.00256	CbGpPWpGaD
Diflunisal—PTGS2—Spinal Cord Injury—TGFB1—systemic scleroderma	1.74e-06	0.00243	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.72e-06	0.0024	CbGpPWpGaD
Diflunisal—PTGS2—Disease—SMAD7—systemic scleroderma	1.66e-06	0.00231	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—NOS3—systemic scleroderma	1.59e-06	0.00222	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—EDN1—systemic scleroderma	1.56e-06	0.00217	CbGpPWpGaD
Diflunisal—PTGS2—Disease—TGFBI—systemic scleroderma	1.51e-06	0.00211	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.39e-06	0.00194	CbGpPWpGaD
Diflunisal—TTR—Disease—NOS3—systemic scleroderma	1.36e-06	0.00189	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—HSPG2—systemic scleroderma	1.27e-06	0.00178	CbGpPWpGaD
Diflunisal—PTGS2—Disease—HSPG2—systemic scleroderma	1.21e-06	0.00169	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.19e-06	0.00166	CbGpPWpGaD
Diflunisal—PTGS2—Disease—CSK—systemic scleroderma	1.17e-06	0.00163	CbGpPWpGaD
Diflunisal—PTGS2—Disease—CD247—systemic scleroderma	1.1e-06	0.00153	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—CCL2—systemic scleroderma	1.07e-06	0.00149	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—HSPG2—systemic scleroderma	1.01e-06	0.00141	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—CTGF—systemic scleroderma	9.66e-07	0.00135	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—NOS3—systemic scleroderma	9.5e-07	0.00133	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—MMP1—systemic scleroderma	9.18e-07	0.00128	CbGpPWpGaD
Diflunisal—TTR—Disease—TGFB1—systemic scleroderma	8.97e-07	0.00125	CbGpPWpGaD
Diflunisal—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	8.54e-07	0.00119	CbGpPWpGaD
Diflunisal—ALB—Metabolism—HSPG2—systemic scleroderma	8.18e-07	0.00114	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—CTGF—systemic scleroderma	7.67e-07	0.00107	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—MMP9—systemic scleroderma	7.62e-07	0.00106	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—NOS3—systemic scleroderma	6.66e-07	0.000929	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—TGFB1—systemic scleroderma	6.28e-07	0.000876	CbGpPWpGaD
Diflunisal—ALB—Metabolism—CTGF—systemic scleroderma	6.2e-07	0.000865	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—TGFB1—systemic scleroderma	4.4e-07	0.000614	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—NOS3—systemic scleroderma	4.2e-07	0.000586	CbGpPWpGaD
Diflunisal—PTGS2—Disease—NOS3—systemic scleroderma	3.98e-07	0.000556	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—NOS3—systemic scleroderma	3.34e-07	0.000466	CbGpPWpGaD
Diflunisal—ALB—Metabolism—NOS3—systemic scleroderma	2.7e-07	0.000377	CbGpPWpGaD
Diflunisal—PTGS2—Disease—TGFB1—systemic scleroderma	2.63e-07	0.000368	CbGpPWpGaD
